Small Cap Feast

7th June 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 


Delistings: 





Whats baking in the oven?

Potential**** Initial Public Offerings:

ITF announced:

22nd May: Raspberry Pi announces an intention to float onto the Premium listing segment of the Main Market. Raspberry Pi is a designer and developer of high-performance, low-cost single board computers and compute modules for industrial IoT customers and embedded uses, as well as for enthusiasts and educators, in markets worldwide. The Company is looking to raise $40m, the net proceeds of which will be used by the Company for engineering capital expenditure, to enhance its supply chain resilience and for other general corporate purposes. The Group's revenue was $140.6m, $187.9m and $265.8m and gross profit was $41.9m, $42.3m and $66.0m in the years ended 31 December 2021, 2022, and 2023, respectively.

4th June: Advanced Oxygen Therapy Inc (AOTI): The medical technology group with a proprietary therapy for the reduction in hospitalisations and amputations caused by non-healing wounds, particularly diabetic foot ulcers, announces its Schedule One and expected first day of trading on the AIM market of the 18th June. The Group expects to raise $25m.

Media speculation:

2nd June: Online fashion firm Shein from China is preparing to file a prospectus ahead of a potential London float which could value it around £50bn.


Reverse Takeovers:


Change of Market:

Dual Listing :


Banquet Buffet

Corcel 0.115p £2.2m (CRCL.L)

The pan Angola-Brazil focused exploration and production company provided the following updates; the near-term focus in Angola will be on geological and geophysical (G&G) activities. The Company announces that the KON 11, KON 12, and KON 16 blocks have received all relevant approvals to acquire new G&G data through an Enhanced Full Tensor Gradiometry Survey. Following the appointment of Scott Gilbert as Interim CEO, as announced on April 25th, 2024, Mr. Gilbert, together with the management team, is progressing with the Company's operational activities in Angola to continue to pursue the potential which its current asset portfolio has to offer, while developing M&A opportunities in Brazil.

Helios Underwriting 186p £139.0m (HUW.L)

The only publicly traded investment company offering instant access to a diverse portfolio at Lloyd's of London, the world's largest insurance market today announces that Martin Reith has stepped down from his role as Chief Executive Officer, to pursue other opportunities. Michael Wade, currently Non-Executive Chairman, will become Executive Chairman with immediate effect as the search for Martin's successor begins. Nigel Hanbury, currently Executive Deputy Chairman, will become Non-Executive Deputy Chairman.

Kibo Energy * 0.016p £0.7m (KIBO.L)

The clean/renewable energy-focused development company announces a corporate restructuring plan, including proposed board changes, a divestment programme, placing and restructuring of the Company's balance sheet. Partly conditional fundraise with gross proceeds of £500k raised at a placing price of 0.015p. Mohammed Ashraf proposed to join Kibo as Executive Director and Chief Executive Officer. James Parsons proposed to join Kibo as Non-Executive Director with specific focus on overseeing and implementing the restructuring. Stefania Barbaglio proposed to join Kibo as Non-Executive Director and Chairperson. Clive Roberts proposed to join Kibo as Non-Executive Director. Debt reduced to a more sustainable level with no conversion rights with all MED's related assets used as collateral to further de-leverage the Company over time.

Ondine Biomedical 7.25p £20.1m (OBI.L)

The provider of light-activated antimicrobial technology to treat and prevent hospital infections announces its audited results for the year ended 31 December 2023. Revenue increased to $1.2m (2022: $0.6m), net loss for the year decreased to $14.4m (2022: $19.4m) and cash decreased to $2.9m (2022: $13.1m). The Company achieved their target goal of 10 new hospital deployments. Of note is the first adoption of Steriwave within the NHS in the UK at Pontefract Hospital (Mid Yorkshire NHS Teaching Trust). The Company also made significant progress towards Phase 3 clinical trial preparation and US launch readiness.

Physiomics * 1.45p £2.0m (PYC.L)

The mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions announces that it has been awarded a significant contract by a new UK-based biotech client. This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas. The project involves the use of our proprietary Virtual Tumour technology to help guide the Phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at £161,580 and is anticipated to be completed over the next five months. The project, and associated contract award, is one of the two referred to in the Company's trading update on 3 May 2024.

Safestay 21.5p £14.0m (SSTY.L)

The owner and operator of an international brand of contemporary hostels announces its Final Results for the 12 months to 31 December 2023. Revenue increased 18% to £22.5m (2022: £19.1m), Adjusted EBITDA increased 15% to £6.8m (2022: £5.9m) and the cash balance is £2.0m (2022: £5.2m) due to the acquisition of a freehold property in Edinburgh for £4.3m. Looking forward, bookings as at January 1st are significantly up on last year at £3.7m.

SRT Marine Systems 20p £44.5m (SRT.L)

The provider of maritime domain awareness systems and technologies for security, safety and environmental protection, provided a trading update. Whilst both systems and transceivers businesses are progressing well within the strategic global maritime domain awareness market, it is with considerable disappointment that it now appears likely that new project revenue milestones in the systems business which were expected to be completed in the current financial period will move into the early part of the next financial year. This is due to longer than expected customer contract completion administrative processes, resulting in significantly lower than expected revenues for the current year, which will aggregate to approximately £14m mostly derived from the transceivers division and thus resulting in a loss for the period.

SysGroup 34.5p £16.9m (SYS.L)

The technology partner for delivery and management of cloud, data and security to power Artificial Intelligence and Machine Learning transformation, announces that further to the announcement at 5:11 p.m. on 6 June 2024, it has successfully conditionally completed and closed the conditional oversubscribed Placing and Subscription to raise gross proceeds of £11m at an issue price of 33p per share. Approximately £2m of the proceeds of the Fundraising is intended to be used to fund an internal transformation project to provide the Group with systems utilising AI driven technologies. This will enable the Company to be a true AI adopter and innovator, acting as a live real case study of best practice to customers. Rather than drawing the Group's existing Bank facility, a further £2m will be used to meet the contingent earnout payment due in August 2024 in relation to the acquisition of Truststream Security Solutions Limited.

Trellus Health 1.45p £2.3m (TRLS.L)

A health services Company delivering innovative, scientifically validated programs and technologies designed to facilitate the management of chronic conditions, improve health outcomes and lower the costs of care, announces the appointment of Kevin L. Murphy Jr. as an independent Non-executive Director, effective immediately, and as Chair Designate. It is intended that Kevin will replace Dr. Daniel Mahony as Chair, on the conclusion of the board meeting to be held immediately after the Company's forthcoming annual general meeting on 14 June 2024.

Zenova Group 1.55p £2.2m (ZED.L)

The innovative fire suppression and interdiction Company today announces its results for the year ended 30 November 2023. Revenue increased to £278k (2022: £175k), loss after tax decreased to £1.7m (2022: £2.0m) and a cash balance of £98k (2022: £782k). The Company foresee the promising convergence of positive macro tailwinds in the fire interdiction markets, continued, recognised certification separation between the Zenova product range and the competition, and further exploitation of the Group's growing distributor relationships, which will drive accelerating sales growth for Zenova through the rest of 2024 and beyond.

.

7 June 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram